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Neuroepithelial tumors represent a heterogeneous class of human tumors including benignant and malignant tumors. The
incidence of central nervous system neoplasms ranges from 3.8 to 5.1 cases per 100,000 in the population. Among malignant
neuroepithelial tumors, with regard to PPAR ligands, the most extensively studied were tumors of astrocytic origin and
neuroblastoma. PPARs are expressed in developing and adult neuroepithelial cells, even if with diﬀerent localization and
relative abundance. The majority of malignant neuroepithelial tumors have poor prognosis and do not respond to conventional
therapeutic protocols, therefore, new therapeutic approaches are needed. Natural and synthetic PPAR ligands may represent a
starting point for the formulation of new therapeutic approaches to be used as coadjuvants to the standard therapeutic protocols.
This review will focus on the major studies dealing with PPAR expression in gliomas and neuroblastoma and the therapeutic
implications of using PPAR agonists for the treatment of these neoplasms.
1.NeuroepithelialTumors
Human neuroepithelial tumors are classiﬁed according the
World Health Organization (WHO). The incidence of cen-
tral nervous system (CNS) neoplasms ranges from 3.8 to 5.1
cases per 100,000 in the population. Among neuroepithelial
tumors, with regard to PPAR ligands, the most extensively
studied are tumors of astrocytic origin and neuroblastoma.
Astrocytic tumors are classiﬁed as: (1) Astrocytoma
(WHO grade II), (2) Anaplastic (malignant) astrocytoma
(WHO grade III), (3) Glioblastoma multiforme (WHO
grade IV); (4) Pilocytic astrocytoma noninvasive, (WHO
grade I), (5) Subependymal giant cell astrocytoma (nonin-
vasive, WHO grade I), (6) Pleomorphic xanthoastrocytoma
(noninvasive, WHO grade I) [1–4].
Malignant astrocytic tumors are the most common
primary brain tumors. High-grade gliomas show high
cellular proliferation rate and inﬁltrate the adjacent brain
tissue [5]. They initially respond to radiation and, to a
lesser degree, to chemotherapy; however, they invariably
recur. The malignant gliomas with poor prognosis and fatal
outcome are mainly represented by anaplastic astrocytoma
and glioblastoma.
1.1. Anaplastic Astrocytoma (WHO Grade III). Also known
as malignant astrocytoma and high-grade astrocytoma, it
may arise from a diﬀuse astrocytoma or may arise de
novo without indication of a less malignant precursor
[6]. Histologically, these tumors show increased cellular-
ity, distinct nuclear atypia, and marked mitotic activity
when compared with low-grade astrocytomas. Anaplastic
astrocytomas possess an intrinsic tendency to progress to
glioblastoma. The mean age at diagnosis is approximately
41 years. This tumor primarily aﬀects the cerebral hemi-
spheres. It has a high frequency of TP53 mutations, which2 PPAR Research
is similar to that of low-grade astrocytomas; chromoso-
mal abnormalities are nonspeciﬁc. Many of the genetic
alterations seen in anaplastic astrocytomas involve genes
that regulate cell cycle progression [4]. The mean time to
progression is 2 years. Positive predictive factors include
young age, high performance status, and gross total tumor
resection.
1.2. Glioblastoma (WHO Grade IV). Also known as glioblas-
toma multiforme (GBM), it may develop from low-grade
astrocytomas or anaplastic astrocytomas but more com-
monly it arises de novo without evidence of a less malignant
precursor [7]. GBM, the most common malignant brain
tumor (34%) in adults, is among the most lethal of all
cancers [8]. Histologically, GBMs are anaplastic, cellular
gliomas composed of poorly diﬀerentiated, often pleiomor-
phic astrocytic tumor cells with marked nuclear atypia and
brisk mitotic activity. Typically, they aﬀect adults and are
preferentially located in cerebral hemispheres. Most patients
with GBM survive less than 1 year, thus new therapeutic
strategies are urgently needed [9, 10]. Genetic analyses
suggest that there are two diﬀerent types of glioblastoma:
de novo glioblastoma, which arises from mutated neural
stem cells or progenitor cells, and secondary glioblastoma,
which arises from lower grade tumors. The secondary GBMs
occur in younger patients [11–13]. The peak incidence
occurs between the ages of 45 and 70 years. GBMs have
been associated with more speciﬁc genetic abnormalities
than any other astrocytic neoplasm, but none are speciﬁc.
Ampliﬁcation of the epidermal growth factor receptor locus
is found in approximately 40% of primary GBMs but is
rarely found in secondary glioblastomas; mutations of the
PTEN gene are observed in 45% of primary GBMs and
to a lesser extent in secondary glioblastomas [4]. Loss of
heterozygosity (LOH) of chromosome 10 and loss of an
entire copy of chromosome 10 are the most frequently
observed chromosomal alterations.
1.3. Neuroblastoma. Neuroblastomas are paediatric tumors
originating from neuroblasts in the developing peripheral
nervous system. Most primary tumors (65%) occur within
the abdomen, with at least half of these arising in the adrenal
medulla. Other common sites of disease include the neck,
chest, and pelvis. It is the most common extracranial solid
tumor in childhood and the most frequently diagnosed
neoplasm during infancy [14]. Neuroblastoma accounts for
more than 7% of malignancies in patients younger than
15 years and around 15% of paediatric deaths [15]. The
mortalityishighduetorapidtumorprogressiontoadvanced
stages. The genetic aberration most consistently associated
with poor outcome in neuroblastoma is genomic ampliﬁ-
cation of MYCN, which occurs in roughly 20% of primary
tumors and is strongly correlated with advanced stage of
disease and treatment failure [14, 16, 17]. Deletions of the
shortarmofchromosome1(1p)canbeidentiﬁedin25–35%
of neuroblastomas. These deletions correlate not only with
MYCN ampliﬁcation, but also with advanced disease stage
[18, 19]. However, the gene or genes within chromosome
1p involved in the pathogenesis of neuroblastoma have not
been identiﬁed despite intensive investigation. It has been
suggested that a strategy to halt the malignancy of these
cells could be to induce them to diﬀerentiate towards mature
neurons. Accordingly, several neuroblastoma diﬀerentiation
protocols have been proposed, for instance treatment with
phenyl acetate and retinoic acid [20]. The SH-SY5Y cell line
wasestablishedfromahighmalignanttumorwithnoN-myc
ampliﬁcation [21]. Treatment of this cell line with phorbol
esters leads to sympathetic neuronal diﬀerentiation with
neurite outgrowth and increased synthesis of noradrenaline
and expression of neuropeptide Y and growth-associated
protein 43 (GAP-43) [22]. These eﬀects are mediated by and
dependent on PKC [20, 23, 24].
1.4. PPARs. The peroxisome proliferator-activated receptor
(PPAR) family of nuclear receptors are ligand-activated
transcription factors which have been implicated in diﬀerent
human pathologies. PPARγ ligands are currently used for
treatment of type II diabetes, PPARα ligands are used to
treat cardiovascular diseases [25–27]. After the isolation of
PPARα (NR1C1), in 1990 by Issemann and Green [28]a s
the nuclear receptor mediating peroxisome proliferation by
peroxisome proliferators (PP) in rodent hepatocytes, two
related isotypes, PPARβ/δ (NR1C2; referred to as PPARβ)
and PPARγ (NR1C3) have been characterized [29]. Since
then, these receptors have been linked to many systemic
and cellular functions ranging far beyond the process after
which they were initially named. Like the other members
of the superfamily, PPARs have a canonical nuclear receptor
organization [30]. The DNA-binding domain, named the C
domain, is highly conserved and its zinc ﬁnger domain is
a common attribute of all members of the nuclear receptor
(NR) superfamily. The C domain is linked to the C-terminal
ligand-binding domain (LBD), named the E domain, by
the hinge region, named the D domain. The LBD contains
a ligand-dependent transactivation function referred to as
AF-2 and comprises 12α helices and 4β sheets that fold
to create a large hydrophobic cavity where ligands are
buried [31]. In addition, the E domain oﬀers the main
surface for dimerization with the 9-cis retinoic acid receptor
(RXR) as well as for interaction with regulatory proteins
called cofactors. The N-terminal domain, named the A/B
domain, is involved in ligand-independent regulation of
receptor activity [32]; this domain harbors a weak-ligand-
independent transactivation function, called AF-1. PPARs
form heterodimers with the RXR and exhibit ligand-induced
transcriptional regulatory activity through sequence-speciﬁc
PPAR-responsive elements (PPRE) in their target genes
[33]. Free PPARs may be associated with corepressors that
inactivate the transcription function of the nuclear receptor.
When the nuclear receptor is activated by a particular ligand
binding to the ligand binding domain, this results in confor-
mational changes to PPAR, and the receptor is released from
binding with the corepressor. PPAR forms a heterodimeric
complex with RXR and then recruits coactivator proteins.
This complex binds to a PPRE on DNA and regulates tran-
scription.Peroxisomeproliferators,likefattyacids,modulatePPAR Research 3
tissue-speciﬁc responses; for example, they stimulate the
expression of enzymes involved in lipid catabolism, namely,
the peroxisomal β-oxidation system [34, 35].
PPARs exhibit a broad but isotype-speciﬁc tissue expres-
sion pattern which can account for the variety of cellular
functions they regulate. PPARα and γ transcripts appear
late during fetal development of rat and mouse (day 13.5
of gestation), with a pattern of expression similar to their
adult distribution, with the exception of the placenta tissue,
where PPARγ is abundantly expressed as early as E8.5 [36,
37]. It has been demonstrated that PPARγ functions in the
placenta are crucial for trophoblast terminal diﬀerentiation
and consequently for placental vascularization and integrity
[37]. In the adipose tissue, the two PPARγ isoforms, γ1
and γ2, act in the brown and white tissues, respectively, to
promote adipocyte diﬀerentiation and lipid storage, while
the expression of the PPARγ1 is preferentially shown in
other tissues such as the gut or the immune cells [38].
PPARα is expressed in tissues with high fatty acid catabolism
such as the liver, heart, skeletal muscle, adrenal gland and
pancreas, kidney, and intestine. In comparison with the
two other isotypes, PPARβ/δ is expressed more ubiquitously
and earlier during fetal development [39]. Its transcript is
present in all organ tested, and it is often more abundant
than the PPARα and γ transcripts [40]. Shi et al. and Bastie
have suggested the involvement of unliganded PPARβ/δ in
modulating the expression and transcriptional activity of the
other two PPARs [41, 42]. In addition, it has been shown
that it is required for placenta development, in the control
of cell proliferation and survival, especially in keratinocytes
and enterocytes, and in the control of lipid metabolism, even
though the underlying mechanisms still need investigations
[43].
F o rm o r et h a nad e c a d e ,w o r ko nP P A R sw a sd r i v e nb y
their important role in the regulation of cellular metabolism,
PPARα in tissues known for high β-oxidation rates such
as liver, heart, muscle, and kidney [44], while PPARγ was
mainly studied for its adipogenic activity. At present, they
are receiving growing attention for their involvement in the
regulation of cell proliferation, death, and diﬀerentiation of
both normal and malignant cells.
1.5. PPAR Ligands. PPARs are activated by a wide range of
naturally occurring or metabolically produced lipids derived
from the diet or from endogenous lipid molecules func-
tioning in intracellular signalling pathways, which include
saturated and unsaturated fatty acids and fatty acid deriva-
tives such as prostaglandins and leukotrienes [45]. Whereas
most natural agonists bind with a relatively weak aﬃnity
(in the order of ¯molar concentration), some high-aﬃnity
endogenous ligands have been characterized [46, 47]. Inter-
estingly, some ligands, including 15-deoxy-prostaglandin J2
(15d-PGJ2), associate irreversibly to the receptor through
covalent binding [48]. The delivery of PPAR ligands to the
nucleus, where the receptors reside, is achieved by diﬀerent
cellular fatty acid binding proteins (FABPs), which are
thought to speciﬁcally interact with the three PPAR isotypes
[49]. PPARα agonists include both ﬁbrates commonly used
for the treatment of hypertriglyceridemia and the synthetic
agonists WY 14,643 and GW7647. The best-characterized
PPARγ agonists are thiazolidinediones (TZDs), including
pioglitazoneandrosiglitazone,whichhaveinsulinsensitizing
activity and are currently used for the treatment of type
2 diabetes (Actos and Avandia, respectively) [44]. There
are a number of nonTZD based PPARγ agonists, such as
GW347845 and others that have been synthesized.
Apart from well-deﬁned metabolic actions, PPARγ ago-
nists exhibit several antineoplastic eﬀects [50] and induce
apoptotic cell death in various malignant cell lineages,
including liposarcoma [51], breast adenocarcinoma [52, 53],
prostate carcinoma [54], colorectal carcinoma [55, 56],
nonsmall-cell lung carcinoma [57], pancreatic carcinoma
[58], bladder cancer [59], and gastric carcinoma [60].
PPARβ/δ agonists include the prostacyclin PGI2, oleic
acid, and the agents, GW0742, GW501516 and GW7842.
2.PPARs inthe Brain
All three PPAR isotypes are coexpressed in the rat CNS
during late embryogenesis, with PPARβ/δ being the more
abundantly and precociously expressed. The expression of
the three PPAR isotypes peaks in the rat CNS between day
13.5 and 18.5 of gestation. Whereas PPARβ/δ remains highly
expressed, the expression of PPARα and PPARγ decreases
postnatally in the brain [61]. Both in vitro and in vivo
observations show that PPARβ/δ is the prevalent isoform in
the brain, found in all nervous cell types, whereas PPARα
is expressed at very low levels predominantly in astrocytes
[30]. Acyl-CoA synthetase 2 (ACS2), an enzyme crucial for
fatty acid activation and utilization, is regulated by PPARβ/δ
at the transcriptional level, providing a simple measure
of PPARβ/δ action [62]. ACS2 has a role in maturation
of neurons (i.e., their cytodiﬀerentiation and formation of
neuronal connectivity); in addition, its over-expression in
PC12 cells enhances internalization of fatty acids, namely
oleicacid(OA),arachidonicacid(AA),anddocosahexaenoic
acid (DHA) and promotes neurite outgrowth [63]. These
observations strongly suggest that PPARβ/δ participates in
the regulation of lipid metabolism in the brain, a hypothesis
further supported by the observation that PPARβ/δ null
mice exhibit an altered myelination of the corpus callosum
[64].Thefactthatnocytoarchitecturalalterationsofcerebral
cortex was described is in contrast with the results obtained
by Michalik et al. and Cimini et al., demonstrating the
existence of a close correlation between PPARβ/δ and ACS2
in PPARβ/δ null mice brain and in the rat cortical neurons,
respectively [65, 66]. However, the study from Peters et al. is
a mainly in situ study and may be only in apparent contrast
with other authors because it does not exclude that neuronal
function and competence may be impaired in PPARβ/δ null
mice [64].
All PPARs have been described in the adult and devel-
oping brain and spinal cord [67–69]. While PPARβ/δ has
been found in neurons of numerous brain areas, PPARα
and PPARγ have been localized to more restricted brain
areas [67, 68]. The localization of PPARs has been also4 PPAR Research
investigated in puriﬁed cultures of neural cells. Previous
studies have reported that PPARβ/δ is strongly expressed in
immature oligodendrocytes (OL) where its activation pro-
motes diﬀerentiation; PPARγ is mainly present in microglia,
while astrocytes possess all three PPAR isotypes, although to
diﬀerent degrees depending on the brain area and animal
age [70–74]. The role of PPARs in the CNS has mainly
been related to lipid metabolism but these receptors have
been recently implicated in neural cell diﬀerentiation and
death as well as in inﬂammation and neurodegeneration
[36]. PPARα has been suggested to be involved in astrocyte
maturation and diﬀerentiation both in primary adult mouse
astroglial cells and in adult neural stem cells (NSC) [75–77].
In addition, this isotype has been suggested to be involved
in acetylcholine metabolism and oxidative stress defense
[68, 78].
PPARγ,besidesplayingaroleinearlyphasesofoligoden-
drocyte diﬀerentiation, has been mainly studied in relation
to inﬂammation, cancer, and neurodegeneration [79]. Con-
cerningPPARβ/δ,itsinvolvementinneuronaldiﬀerentiation
andinCNSdevelopmenthasbeensuggestedbyBasu-Modak
et al., Michalik et al., Braissant and Whali, on the basis of
i t sh i g hl e v e l si nr a tn e u r a lt u b e ,i nr e a g g r e g a t e dn e u r a lc e l l
cultures and in adult CNS [62, 65, 80]. Roles for PPARβ/δ
in the regulation of pain sensation and transmission in
adult spinal cord [69] and in learning and memory in
mouse hippocampus and in entorhinal cortex have been
proposed [67, 69]. In a previous work we showed that
PPARβ/δ is the main isotype present in primary cultures of
rat cortical neurons, where it seems necessary for neuronal
maturation together with the reduction of PPARγ expression
and the activation of PPARα;P P A R β/δ, in fact, is gradually
increased and activated during neuronal maturation, and
this increase correlates with the expression of its target gene
ACS2 [81].
3.PPARsinNeuroepithelialTumors
Among neuroepithelial tumors, gliomas, especially glioblas-
toma and neuroblastoma, have been the most extensively
studied as to regard PPARs, and in this context, the PPARγ
isotype was the most extensively studied.
3.1. PPARs and GBM. Glioblastoma expresses all three
PPAR isotypes both in vitro and in situ.T h em a j o r i t yo f
the studies performed on this neoplasm, both on rat and
human gliomas, reported on the antiproliferative activity
of diﬀerent PPARγ ligands, both natural and synthetic,
by promoting apoptotic cell death or by increasing reac-
tive oxygen species production [82–86]. PPARγ has been
identiﬁed in transformed neural cells of human origin,
and PPARγ agonists have been shown to decrease cell
proliferation,stimulateapoptosis,andinducemorphological
c h a n g e sa sw e l la se x p r e s s i o no fm a r k e r st y p i c a lo fam o r e
diﬀerentiated phenotype in glioblastoma and astrocytoma
cell lines [87–89]. These ﬁndings have more recently been
conﬁrmed in glioblastoma primary cultures; treating pri-
mary cultures of gliobalstoma cells with natural or synthetic
PPARγ ligands decreases the expression of markers of undif-
ferentiated stages, such as CD133, nestin and ﬁbronectin,
while increasing the expression of diﬀerentiation markers
such as A2B5, GFAP, β-catenin, and N-cadherin. Conju-
gated linoleic acid (CLA) and the PPARγ synthetic agonist
GW347845 also suppress proliferation and induce apoptosis
in primary cultures of glioblastoma cells [90]. Consistent
with growth inhibition, both ligands downregulate cyclinD1
and CDk4 protein levels, while inducing the transcription
of the tumor suppressor gene PTEN. Both CLA and PPARγ
agonist lead to a signiﬁcant decrease of the VEGF isoforms
and NOSII, thus indicating that even in glioblastoma PPARγ
is able to inhibit the angiogenic pathways [90]. It has
also been reported that ciglitazone induces apoptosis in
four human glioblastoma cell lines by decreasing cyclin D1
and Bcl-2 proteins and increasing p27 and p21 proteins
[91, 92]. Finally, there is some evidence to suggest that
TZDs are potent inhibitors of glioma cell migration and
brain invasion largely by transcriptional repression of TGF-
β [93]. This is particularly important because TGF-β is an
immunosuppressive cytokine that has been shown to play
a major role in the malignant phenotype of gliomas [94].
Furthermore,inhibitionofTGF-β signalingrestoresimmune
surveillance and is associated with improved survival in a
glioma model [95].
Apoptosis-based therapies gained interest as promising
experimental treatment strategies since direct induction of
apoptotic cell death can overcome many of the classical
resistance mechanisms such as activated DNA repair or
detoxiﬁcation. The death ligand TRAIL/Apo2L might be a
useful tool to trigger apoptosis in cancer, since TRAIL kills
tumor cells of diverse cellular origin without severe toxic side
eﬀects [96, 97]. However, despite the common expression of
death receptors, not all glioblastoma cells are susceptible to
TRAIL, due to intracellular blockage of apoptotic signalling
cascades. A group of PPARγ-modulating agents sensitize
tumor cells to TRAIL-induced apoptosis [98]. It has been
reported that glioblastoma cells are sensitized to TRAIL-
induced apoptosis by troglitazone via various mechanisms.
Troglitazone lead to a marked down-regulation of the
antiapoptotic proteins FLIP and Survivin. Moreover, in
some cell lines, the cell surface expression of agonistic
and antagonistic TRAIL receptors was altered towards a
higher susceptibility to death receptor-induced apoptosis.
Troglitazone might counteract the capability of tumor cells
tobecomeresistanttoapoptosisbymodulatingtheapoptotic
machinery at diﬀerent levels [98].
It should be noted that only PPARγ ligands have been
described as antiproliferative compounds in gliomas; no
eﬀects have been reported for other PPAR ligands. However,
some evidences, obtained by us [99]i nh u m a ng l i o m a s
at diﬀerent grades of malignancy, strongly indicate an
upregulation of PPARα and its direct relationship with
malignancy grade, suggesting that PPARα antagonists can be
used to halt malignancy, and suggesting that in some cases
dual PPAR agonists should be carefully used.
Taken together, these data reported in glioma cells
indicate that PPARγ activation by both synthetic and naturalPPAR Research 5
ligands,resultsincellcyclearrest,apoptosispromotion,inhi-
bitionofcellmigrationandinvasionaswellassuppressionof
antiapoptotic proteins, induction of diﬀerentiation markers,
thus suggesting their potential use in the formulation of new
therapeutic strategies against this neoplasm and recurrences.
3.2. PPARs and Neuroblastoma. Neuroblastoma cells express
all three isotypes of PPARs. PPARγ is present in neuroblas-
toma cell lines [100], as well as in primary neuroblastoma
cell culture [50]. Few studies report the expression of PPARα
at mRNA or protein level in human neuroblastoma cell
lines [101] and data on the expression of PPARβ/δ in
neuroblastomas are scarce [102]. To assess the roles of PPARs
on neuroblastoma, most studies evaluate the impact of their
natural or synthetic ligands on cell proliferation, death and
diﬀerentiation. The putative natural PPARγ agonist, 15d-
PGJ2, inhibits cellular growth, decreases cellular viability
and induces apoptosis in human neuroblastoma cells in
vitro [100, 103, 104], although some eﬀects have been
demonstrated to be PPARγ-independent [105]. Rodway et
al. [103] showed that the PPARα agonist WY-14643 has
no eﬀect on the growth of the IMR32 neuroblastoma cell
line, whereas PGJ2 induces growth inhibition in the same
neuroblastoma cells. This occurs through programmed cell
death type II or autophagy, and the serum lysolipid, the
lysophosphatidic acid (LPA), is responsible for modulating
this cellular response. In the neuroblastoma cell line ND-7,
the same group showed that the degree of PPARγ activation
induced by PGJ2 is modulated through an interaction with
the retinoblastoma protein (Rb) and histone deacetylase
[106]. A combination therapy consisting of PGJ2 and the
histone deacetylase inhibitor trichostatin A enhances the
growth inhibition eﬀects and is therefore proposed as a
promisingnewstrategyinthetreatmentofneuroblastoma.It
should be noted that the eﬀects of 15d-PGJ2 can also depend
on its action on the NFκBp a t h w a y[ 107]. Valentiner et al.
[108] tested foursynthetic PPARγ TZD agonists (ciglitazone,
pioglitazone, troglitazone, rosiglitazone) and reported their
in vitro eﬀects on cell growth of seven human neuroblastoma
cell lines (Kelly, LAN-1, LAN-5, LS, IMR-32, SK-N-SH, and
SH-SY5Y).AllTZDsinhibitedcellgrowthandviabilityofthe
cells in a dose-dependent manner, whereas the eﬀectiveness
of the single drugs was strongly diﬀerent among cell lines.
Similar results for ciglitazone and rosiglitazone have been
reported [100, 109]. Cellai and colleagues [109] showed that
high concentrations of rosiglitazone in vitro signiﬁcantly
inhibit cell adhesion, invasiveness, and apoptosis in SK-N-
AS, but not in SH-SY5Y human neuroblastoma cells. The
authors argued that this eﬀect may be related to cellular
diﬀerences in PPARγ transactivation. We have recently
demonstrated[110]thatPPARβ/δ agonists,bothnaturaland
synthetic (oleic acid and GW0742, respectively), are able to
induce cell cycle arrest in G1 phase and neuronal diﬀeren-
tiation in human neuroblastoma cell line SH-NH-5YSY by
increasing p16 levels and decreasing cyclin D1 levels as well
as by inducing the expression of neuronal diﬀerentiation
markers and downregulating TrκB full length expression.
In the case of neuroblastoma, both PPARγ and PPARβ/δ
ligandsshowedantiproliferativeeﬀectsbutitshouldbenoted
that PPARγ activation results in apoptosis promotion, while
PPARβ/δ activation results in cell cycle arrest and neuronal
diﬀerentiation, thus suggesting the possibility to use dual
agonists to counteract tumor progression and recurrences.
4.FuturePerspectives
The majority of malignant neuroepithelial tumors have poor
prognosis and do not respond to conventional therapeutic
protocols. Studying and validating both natural and syn-
thetic PPAR ligands may represent a starting point for the
formulation of new therapeutic approaches to be used as
coadjuvants to the standard therapeutic protocols. Another
point to be considered is the targeting eﬃciency of these
new drugs. The progress in the understanding of the biology
and genetic of neuroepithelial tumors together with the
use of truly manipulable experimental models, now oﬀer
real opportunities for the development of eﬀective targeted
therapy. Despite signiﬁcant gaps in our understanding, a
wealth of information now exists about the clinical and
biological behaviours of these tumors, the genetic pathways
involved in tumorigenesis, and the nature and role of
signature alterations in these pathways. The challenge now
is to integrate this knowledge in an interdisciplinary way
to fully understand these diseases, particularly how their
signature heterogeneity contributes to their intractability
in order to design eﬃcient drugs delivered exclusively to
malignant cells.
References
[1] W. K. Cavenee, F. B. Furnari, M. Nagane, et al., “Diﬀusely
inﬁltrating astrocytomas,” in Pathology and Genetics of
Tumours of the Nervous System, P. Kleihues and W. K.
Cavenee, Eds., pp. 10–21, International Agency for Research
on Cancer, Lyon, France, 2000.
[2] P. C. Burger, B. W. Scheithauer, W. Paulus, et al., “Pilocytic
astrocytoma,” in Pathology and Genetics of Tumours of the
Nervous System, P. Kleihues and W. K. Cavenee, Eds., pp.
45–51, International Agency for Research on Cancer, Lyon,
France, 2000.
[3] P. Kleihues, R. L. Davis, H. Ohgaki, et al., “Diﬀuse astrocy-
toma,” in Pathology and Genetics of Tumours of the Nervous
System, P. Kleihues and W. K. Cavenee, Eds., pp. 22–26,
International Agency for Research on Cancer, Lyon, France,
2000.
[4] G. J. Kitange, K. L. Templeton, and R. B. Jenkins, “Recent
advances in the molecular genetics of primary gliomas,”
Current Opinion in Oncology, vol. 15, no. 3, pp. 197–203,
2003.
[5] P. Kleihues, R. L. Davis, S. W. Coons, et al., “Anaplastic
astrocytoma,” in Pathology and Genetics of Tumours of the
Nervous System, P. Kleihues and W. K. Cavenee, Eds., pp.
27–28, International Agency for Research on Cancer, Lyon,
France, 2000.
[6] P. Kleihues, P. C. Burger, V. P. Collins, et al., “Glioblastoma,”
in Pathology and Genetics of Tumours of the Nervous System,
P. Kleihues and W. K. Cavenee, Eds., pp. 29–39, International
Agency for Research on Cancer, Lyon, France, 2000.6 PPAR Research
[7] J. G. Gurney and N. Kadan-Lottick, “Brain and other central
nervous system tumors: rates, trends, and epidemiology,”
Current Opinion in Oncology, vol. 13, no. 3, pp. 160–166,
2001.
[8] H. Jiang, C. Conrad, J. Fueyo, C. Gomez-Manzano, and T. J.
Liu, “Oncolytic adenoviruses for malignant glioma therapy,”
Frontiers in Bioscience, vol. 8, pp. d577–d588, 2003.
[ 9 ]X .F a n ,Y .A a l t o ,S .G .S a n k o ,S .K n u u t i l a ,D .K l a t z m a n n ,
and J. S. Castresana, “Genetic proﬁle, PTEN mutation and
therapeutic role of PTEN in glioblastomas,” International
Journal of Oncology, vol. 21, no. 5, pp. 1141–1150, 2002.
[10] N. Ishii, D. Maier, A. Merlo, et al., “Frequent co-alteration
of TP53, p16/CDKN 2S, p14ARF, PTEN tumor suppressor
genes in human glioblastoma cell lines,” Brain Pathology, vol.
9, pp. 469–479, 1999.
[11] P. Kleihues and W. K. Cavenee, Eds., Pathology and Genetics
of Tumours of the Nervous System, International Agency for
Research on Cancer, Lyon, France, 2000.
[ 1 2 ] P .K l e i h u e s ,D .N .L o u i s ,B .W .S c h e i t h a u e r ,e ta l . ,“T h eW H O
classiﬁcation of tumors of the nervous system,” Journal of
Neuropathology and Experimental Neurology, vol. 61, no. 3,
pp. 215–225, 2002.
[13] D. A. Reardon, J. N. Rich, H. S. Friedman, and D. D.
Bigner, “Recent advances in the treatment of malignant
astrocytoma,” Journal of Clinical Oncology, vol. 24, no. 8, pp.
1253–1265, 2006.
[14] G. M. Brodeur, R. C. Seeger, M. Schwab, H. E. Varmus,
and J. M. Bishop, “Ampliﬁcation of N-myc in untreated
human neuroblastomas correlates with advanced disease
stage,” Science, vol. 224, no. 4653, pp. 1121–1124, 1984.
[15] National Cancer Institute, “Surveillance, Epidemiology
and End Results Database,” November, 2005,
http://seer.cancer.gov/.
[16] M. Schwab, G. P. Tonini, and J. Benard, Human Neurob-
lastoma. Recent Advances in Clinical and Genetic Analysis,
Harwood Academic Publishers, Chur, Switzerland, 1993.
[17] R. C. Seeger, G. M. Brodeur, H. Sather, et al., “Association
of multiple copies of the N-myc oncogene with rapid
progression of neuroblastomas,” The New England Journal of
Medicine, vol. 313, no. 18, pp. 1111–1116, 1985.
[18] P. S. White, P. M. Thompson, B. A. Seifried, et al., “Detailed
molecular analysis of 1p36 in neuroblastoma,” Medical and
Pediatric Oncology, vol. 36, no. 1, pp. 37–41, 2001.
[19] P.S.White,P.M.Thompson,T.Gotoh,etal.,“Deﬁnitionand
characterization of a region of 1p36.3 consistently deleted in
neuroblastoma,” Oncogene, vol. 24, no. 16, pp. 2684–2694,
2005.
[20] N. Sidell, “Retinoic acid-induced growth inhibition and
morphologic diﬀerentiation of human neuroblastoma cells
in vitro,” Journal of the National Cancer Institute, vol. 68, no.
4, pp. 589–596, 1982.
[21] J. L. Biedler, L. Helson, and B. A. Spengler, “Morphology
and growth, tumorigenicity, and cytogenetics of human
neuroblastoma cells in continuous culture,” Cancer Research,
vol. 33, no. 11, pp. 2643–2652, 1973.
[22] S. Pahlman, L. Odelstad, E. Larsson, G. Grotte, and K.
Nilsson, “Phenotypic changes of human neuroblastoma
cells in culture induced by 12-O-tetradecanoyl-phorbol-13-
acetate,” International Journal of Cancer,v o l .2 8 ,n o .5 ,p p .
583–589, 1981.
[23] V. Parrow, E. Nanberg, J. Heikkila, U. Hammerling, and
S. Pahlman, “Protein kinase C remains functionally active
during TPA induced neuronal diﬀerentiation of SH-SY5Y
human neuroblastoma cells,” Journal of Cellular Physiology,
vol. 152, no. 3, pp. 536–544, 1992.
[24] S. Fagerstr¨ o m ,S .P ˚ ahlman, C. Gestblom, and E. N˚ anberg,
“Protein kinase C-ε is implicated in neurite outgrowth in
diﬀerentiating human neuroblastoma cells,” Cell Growth and
Diﬀerentiation, vol. 7, no. 6, pp. 775–785, 1996.
[25] J. van Wijk, B. Coll, M. C. Cabezas, et al., “Rosiglitazone
modulates fasting and post-prandial paraoxonase 1 activity
in type 2 diabetic patients,” Clinical and Experimental
Pharmacology and Physiology, vol. 33, no. 12, pp. 1134–1137,
2006.
[26] W. Linz, P. Wohlfart, M. Baader, et al., “The peroxi-
some proliferator-activated receptor-α (PPAR-α) agonist,
AVE8134, attenuates the progression of heart failure and
increases survival in rats,” Acta Pharmacologica Sinica, vol.
30, no. 7, pp. 935–946, 2009.
[ 2 7 ] A .G a l l i ,T .M e l l o ,E .C e n i ,E .S u r r e n t i ,a n dC .S u r r e n t i ,“ T h e
potential of antidiabetic thiazolidinediones for anticancer
therapy,” Expert Opinion on Investigational Drugs, vol. 15, no.
9, pp. 1039–1049, 2006.
[28] I. Issemann and S. Green, “Activation of a member of
the steroid hormone receptor superfamily by peroxisome
proliferators,” Nature, vol. 347, no. 6294, pp. 645–650, 1990.
[ 2 9 ] C .D r e y e r ,G .K r e y ,H .K e l l e r ,F .G i v e l ,G .H e l f t e n b e i n ,a n dW .
Wahli, “Control of the peroxisomal β-oxidation pathway by a
novel family of nuclear hormone receptors,” Cell, vol. 68, no.
5, pp. 879–887, 1992.
[30] J. N. Feige, L. Gelman, L. Michalik, B. Desvergne, and
W. Wahli, “From molecular action to physiological out-
puts: peroxisome proliferator-activated receptors are nuclear
receptors at the crossroads of key cellular functions,” Progress
in Lipid Research, vol. 45, no. 2, pp. 120–159, 2006.
[31] R. T. Nolte, G. B. Wisely, S. Westin, et al., “Ligand binding
and co-activator assembly of the peroxisome proliferator-
activatedreceptor-γ,” Nature,vol.395,no.6698,pp.137–143,
1998.
[32] S. Kersten and W. Wahli, “Peroxisome proliferator activated
receptor agonists,” EXS, vol. 89, pp. 141–151, 2000.
[33] T. M. Willson, P. J. Brown, D. D. Sternbach, and B. R. Henke,
“The PPARs: from orphan receptors to drug discovery,”
Journal of Medicinal Chemistry, vol. 43, no. 4, pp. 527–550,
2000.
[34] J. P. Vanden Heuvel, “Peroxisome proliferator-activated
receptors: a critical link among fatty acids, gene expression
and carcinogenesis,” Journal of Nutrition, vol. 129, supple-
ment 2, pp. 575S–580S, 1999.
[35] A. Cimini, L. Cristiano, A. Bernardo, S. Farioli-Vecchioli,
S. Stefanini, and M. P. Cer` u, “Presence and inducibility of
peroxisomes in a human glioblastoma cell line,” Biochimica
et Biophysica Acta, vol. 1474, no. 3, pp. 397–409, 2000.
[36] M. T. Heneka and G. E. Landreth, “PPARs in the brain,”
BiochimicaetBiophysicaActa,vol.1771,no.8,pp.1031–1045,
2007.
[37] Y. Barak, Y. Sadovsky, and T. Shalom-Barak, “PPAR signaling
in placental development and function,” PPAR Research, vol.
2008, Article ID 142082, 11 pages, 2008.
[38] P. Escher and W. Wahli, “Peroxisome proliferator-activated
receptors: insight into multiple cellular functions,” Mutation
Research, vol. 448, no. 2, pp. 121–138, 2000.
[39] J. M. Keller, P. Collet, A. Bianchi, et al., “Implications
of peroxisome proliferator-activated receptors (PPARS) in
development, cell life status and disease,” International
Journal of Developmental Biology, vol. 44, no. 5, pp. 429–442,
2000.PPAR Research 7
[40] P. Escher, O. Braissant, S. Basu-Modak, L. Michalik, W.
Wahli, and B. Desvergne, “Rat PPARs: quantitative analysis
in adult rat tissues and regulation in fasting and refeeding,”
Endocrinology, vol. 142, no. 10, pp. 4195–4202, 2001.
[41] Y. Shi, M. Hon, and R. M. Evans, “The peroxisome
proliferator-activated receptor δ, an integrator of transcrip-
tional repression and nuclear receptor signaling,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 99, no. 5, pp. 2613–2618, 2002.
[42] C. Bastie, “PPARδ and PPARγ: roles in fatty acids signalling,
implicationintumorigenesis,”BulletinduCancer,vol.89,no.
1, pp. 23–28, 2002.
[43] L. Michalik, B. Desvergne, and W. Wahli, “Peroxisome
proliferator-activated receptors β/δ: emerging roles for a
previously neglected third family member,” Current Opinion
in Lipidology, vol. 14, no. 2, pp. 129–135, 2003.
[44] T. Lemberger, B. Desvergne, and W. Wahli, “Peroxisome
proliferator-activated receptors: a nuclear receptor signaling
pathway in lipid physiology,” Annual Review of Cell and
Developmental Biology, vol. 12, pp. 335–363, 1996.
[45] J. Berger and D. E. Moller, “The mechanisms of action of
PPARs,” Annual Review of Medicine, vol. 53, pp. 409–435,
2002.
[46] H. A. Hostetler, A. D. Petrescu, A. B. Kier, and F. Schroeder,
“Peroxisome proliferator-activated receptor α interacts with
high aﬃnity and is conformationally responsive to endoge-
nous ligands,” The Journal of Biological Chemistry, vol. 280,
no. 19, pp. 18667–18682, 2005.
[47] F. J. Schopfer, Y. Lin, P. R. S. Baker, et al., “Nitrolinoleic acid:
an endogenous peroxisome proliferator-activated receptor γ
ligand,” Proceedings of the National Academy of Sciences of the
UnitedStatesofAmerica,vol.102,no.7,pp.2340–2345,2005.
[48] T. Shiraki, N. Kamiya, S. Shiki, T. S. Kodama, A. Kakizuka,
and H. Jingami, “α,β-unsaturated ketone is a core moiety
of natural ligands for covalent binding to peroxisome
proliferator-activated receptor γ,” The Journal of Biological
Chemistry, vol. 280, no. 14, pp. 14145–14153, 2005.
[49] N.-S. Tan, N. S. Shaw, N. Vinckenbosch, et al., “Selec-
tive cooperation between fatty acid binding proteins and
peroxisome proliferator-activated receptors in regulating
transcription,” Molecular and Cellular Biology, vol. 22, no. 14,
pp. 5114–5127, 2002.
[50] C. Grommes, G. E. Landreth, and M. T. Heneka, “Antineo-
plastic eﬀects of peroxisome proliferator-activated receptor γ
agonists,” Lancet Oncology, vol. 5, no. 7, pp. 419–429, 2004.
[51] P. Tontonoz, S. Singer, B. M. Forman, et al., “Terminal diﬀer-
entiation of human liposarcoma cells induced by ligands for
peroxisome proliferator-activated receptorγ and the retinoid
Xr ec e pt o r , ”ProceedingsoftheNational AcademyofSciencesof
theUnitedStatesofAmerica,vol.94,no.1,pp.237–241, 1997.
[52] E. Elstner, C. M¨ uller, K. Koshizuka, et al., “Ligands for
peroxisome proliferator-activated receptor γ and retinoic
acid receptor inhibit growth and induce apoptosis of human
breast cancer cells in vitro and in BNX mice,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 95, no. 15, pp. 8806–8811, 1998.
[53] E. Mueller, P. Sarraf, P. Tontonoz, et al., “Terminal Diﬀeren-
tiation of Human Breast Cancer through PPARγ,” Molecular
Cell, vol. 1, no. 3, pp. 465–470, 1998.
[54] T. Kubota, K. Koshizuka, E. A. Williamson, et al., “Ligand for
peroxisome proliferator-activated receptor γ (Troglitazone)
has potent antitumor eﬀect against human prostate cancer
both in vitro and in vivo,” Cancer Research, vol. 58, no. 15,
pp. 3344–3352, 1998.
[55] J.A.Brockman,R.A.Gupta,andR.N.Dubois,“Activationof
PPARγ leads to inhibition of anchorage-independent growth
of human colorectal cancer cells,” Gastroenterology, vol. 115,
no. 5, pp. 1049–1055, 1998.
[ 5 6 ]P .S a r r a f ,E .M u e l l e r ,D .J o n e s ,e ta l . ,“ D i ﬀerentiation and
reversal of malignant changes in colon cancer through
PPARγ,” Nature Medicine, vol. 4, no. 9, pp. 1046–1052, 1998.
[57] T.-H. Chang and E. Szabo, “Induction of diﬀerentiation
andapoptosisbyligandsofperoxisomeproliferator-activated
receptor γ in non-small cell lung cancer,” Cancer Research,
vol. 60, no. 4, pp. 1129–1138, 2000.
[58] W. Motomura, T. Okumura, N. Takahashi, T. Obara, and
Y. Kohgo, “Activation of peroxisome proliferator-activated
receptor γ by troglitazone inhibits cell growth through the
increase of p27(Kip1) in human pancreatic carcinoma cells,”
Cancer Research, vol. 60, no. 19, pp. 5558–5564, 2000.
[59] Y.-F. Guan, Y.-H. Zhang, R. M. Breyer, L. Davis, and M.
D. Breyer, “Expression of peroxisome proliferator-activated
receptor γ (PPARγ) in human transitional bladder cancer
and its role in inducing cell death,” Neoplasia, vol. 1, no. 4,
pp. 330–339, 1999.
[60] H. Sato, S. Ishihara, K. Kawashima, et al., “Expression
of peroxisome proliferator-activated receptor (PPAR)γ in
gastric cancer and inhibitory eﬀects of PPARγ agonists,”
BritishJournalofCancer,vol.83,no.10,pp.1394–1400,2000.
[61] O. Braissant, F. Foufelle, C. Scotto, M. Dauca, and W. Wahli,
“Diﬀerential expression of peroxisome proliferator-activated
receptors (PPARs): tissue distribution of PPAR-α,- β, and -γ
in the adult rat,” Endocrinology, vol. 137, no. 1, pp. 354–366,
1996.
[ 6 2 ]S .B a s u - M o d a k ,O .B r a i s s a n t ,P .E s c h e r ,B .D e s v e r g n e ,P .
Honegger, and W. Wahli, “Peroxisome proliferator-activated
receptorβregulatesacyl-CoAsynthetase2inreaggregatedrat
brain cell cultures,” The Journal of Biological Chemistry, vol.
274, no. 50, pp. 35881–35888, 1999.
[63] J. R. Marszalek, C. Kitidis, A. Dararutana, and H. F.
Lodish, “Acyl-CoA synthetase 2 overexpression enhances
fattyacidinternalizationandneuriteoutgrowth,”TheJournal
of Biological Chemistry, vol. 279, no. 23, pp. 23882–23891,
2004.
[64] J.M.Peters,S.S.T.Lee,W.Li,etal.,“Growths,adipose,brain,
and skin alterations resulting from targeted disruption of
the mouse peroxisome proliferator-activated receptor β(δ),”
MolecularandCellularBiology,vol.20,no.14,pp.5119–5128,
2000.
[65] L. Michalik, B. Desvergne, C. Dreyer, M. Gavillet, R. N.
Laurini, and W. Wahli, “PPAR expression and function
during vertebrate development,” International Journal of
Developmental Biology, vol. 46, no. 1, pp. 105–114, 2002.
[66] A. Cimini, E. Benedetti, L. Cristiano, et al., “Expression
of peroxisome proliferator-activated receptors (PPARs) and
retinoic acid receptors (RXRs) in rat cortical neurons,”
Neuroscience, vol. 130, no. 2, pp. 325–337, 2005.
[67] J. W. Woods, M. Tanen, D. J. Figueroa, et al., “Localization
of PPARδ in murine central nervous system: expression in
oligodendrocytes and neurons,” Brain Research, vol. 975, no.
1-2, pp. 10–21, 2003.
[68] S. Moreno, S. Farioli-vecchioli, and M. P. Cer` u, “Immunolo-
calization of peroxisome proliferator-activated receptors and
retinoid X receptors in the adult rat CNS,” Neuroscience, vol.
123, no. 1, pp. 131–145, 2004.
[69] A. Benani, P. Kr´ emarik-Bouillaud, A. Bianchi, P. Netter, A.
Minn, and M. Dauc ¸a, “Evidence for the presence of both
peroxisomeproliferator-activatedreceptorsalphaandbetain8 PPAR Research
the rat spinal cord,” Journal of Chemical Neuroanatomy, vol.
25, no. 1, pp. 29–38, 2003.
[70] J. Granneman, R. Skoﬀ, and X. Yang, “Member of the perox-
isome proliferator-activated receptor family of transcription
f a c t o r si sd i ﬀerentially expressed by oligodendrocytes,” Jour-
nalofNeuroscienceResearch,vol.51,no.5,pp.563–573,1998.
[ 7 1 ] I .S a l u j a ,J .G .G r a n n e m a n ,a n dR .P .S k o ﬀ,“ P P A Rδ agonists
stimulate oligodendrocyte diﬀerentiation in tissue culture,”
Glia, vol. 33, no. 3, pp. 191–204, 2001.
[72] A. Bernardo, M. A. Ajmone-Cat, G. Levi, and L. Minghetti,
“15-deoxy-Δ12,14-prostaglandin J2 regulates the functional
state and the survival of microglial cells through multiple
molecular mechanisms,” Journal of Neurochemistry, vol. 87,
no. 3, pp. 742–751, 2003.
[73] T. E. Cullingford, K. Bhakoo, S. Peuchen, C. T. Dolphin, R.
Patel, and J. B. Clark, “Distribution of mRNAs encoding the
peroxisome proliferator-activated receptor α, β,a n dγ and
the retinoid X receptor α, β,a n dγ in rat central nervous
system,” Journal of Neurochemistry, vol. 70, no. 4, pp. 1366–
1375, 1998.
[74] L. Cristiano, A. Bernardo, and M. P. Cer` u, “Peroxisome
proliferator-activated receptors (PPARs) and peroxisomes in
rat cortical and cerebellar astrocytes,” Journal of Neurocytol-
ogy, vol. 30, no. 8, pp. 671–683, 2001.
[75] L. Cristiano, A. Cimini, S. Moreno, A. M. Ragnelli, and M. P.
Cer` u, “Peroxisome proliferator-activated receptors (PPARs)
and related transcription factors in diﬀerentiating astrocyte
cultures,” Neuroscience, vol. 131, no. 3, pp. 577–587, 2005.
[76] A. Cimini, L. Cristiano, E. Benedetti, B. D’Angelo, and M.
P. Cer ` u, “PPARs expression in adult mouse neural stem
cells:modulationofPPARsduringastroglialdiﬀerentiaton of
NSC,” PPAR Research, vol. 2007, Article ID 48242, 10 pages,
2007.
[77] A. Cimini and M. P. Cer` u, “Emerging roles of peroxisome
proliferator-activated receptors (PPARs) in the regulation of
neural stem cells proliferation and diﬀerentiation,” Stem Cell
Reviews, vol. 4, no. 4, pp. 293–303, 2008.
[78] S. Farioli-Vecchioli, S. Moreno, and M. P. Cer` u, “Immunocy-
tochemical localization of acyl-CoA oxidase in the rat central
nervous system,” Journal of Neurocytology, vol. 30, no. 1, pp.
21–33, 2001.
[79] M. T. Heneka, T. Klockgether, and D. L. Feinstein, “Per-
oxisome proliferator-activated receptor-γ ligands reduce
neuronal inducible nitric oxide synthase expression and cell
death in vivo,” Journal of Neuroscience, vol. 20, no. 18, pp.
6862–6867, 2000.
[80] O. Braissant and W. Wahli, “Diﬀerential expression of perox-
isome proliferator-activated receptor-α,- β, and -γ during rat
embryonic development,” Endocrinology, vol. 139, no. 6, pp.
2748–2754, 1998.
[81] A. Cimini, E. Benedetti, L. Cristiano, et al., “Expression
of peroxisome proliferator-activated receptors (PPARs) and
retinoic acid receptors (RXRs) in rat cortical neurons,”
Neuroscience, vol. 130, no. 2, pp. 325–337, 2005.
[82] C. Grommes, G. E. Landreth, U. Schlegel, and M. T.
Heneka, “The nonthiazolidinedione tyrosine-based perox-
isome proliferator-activated receptor γ ligand GW7845
induces apoptosis and limits migration and invasion of
rat and human glioma cells,” Journal of Pharmacology and
ExperimentalTherapeutics,vol.313,no.2,pp.806–813,2005.
[83] T. Zander, J. A. Kraus, C. Grommes, et al., “Induction of
apoptosis in human and rat glioma by agonists of the nuclear
receptor PPARγ,” Journal of Neurochemistry, vol. 81, no. 5,
pp. 1052–1060, 2002.
[84] J. M. P´ erez-Ortiz, P. Tranque, C. F. Vaquero, et al., “Glita-
zones diﬀerentially regulate primary astrocyte and glioma
cell survival: involvement of reactive oxygen species and
peroxisome proliferator-activated receptor-γ,” The Journal of
Biological Chemistry, vol. 279, no. 10, pp. 8976–8985, 2004.
[85] K. Berge, K. J. Tronstad, E. N. Flindt, et al., “Tetradecylth-
ioacetic acid inhibits growth of rat glioma cells ex vivo and in
vivo via PPAR-dependent and PPAR-independent pathways,”
Carcinogenesis, vol. 22, no. 11, pp. 1747–1755, 2001.
[86] C. Grommes, G. E. Landreth, M. Sastre, et al., “Inhibition
of in vivo glioma growth and invasion by peroxisome
proliferator-activated receptor γ agonist treatment,” Molec-
ular Pharmacology, vol. 70, no. 5, pp. 1524–1533, 2006.
[87] N. Chattopadhyay, D. P. Singh, O. Heese, et al., “Expression
of peroxisome proliferator-activated receptors (PPARs) in
human astrocytic cells: PPARγ agonists as inducers of
apoptosis,” Journal of Neuroscience Research, vol. 61, no. 1,
pp. 67–74, 2000.
[88] R. Morosetti, T. Servidei, M. Mirabella, et al., “The PPARγ
ligands PGJ2 and rosiglitazone show a diﬀerential ability to
inhibit proliferation and to induce apoptosis and diﬀerentia-
tion of human glioblastoma cell lines,” International Journal
of Oncology, vol. 25, no. 2, pp. 493–502, 2004.
[89] A. Cimini, L. Cristiano, S. Colafarina, et al., “PPARγ-
dependent eﬀects of conjugated linoleic acid on the human
glioblastomacellline(ADF),”InternationalJournalofCancer,
vol. 117, no. 6, pp. 923–933, 2005.
[90] A. Spagnolo, E. N. Grant, R. Glick, T. Lichtor, and D. L.
Feinstein, “Diﬀerential eﬀects of PPARγ agonists on the
metabolicpropertiesofgliomasandastrocytes,”Neuroscience
Letters, vol. 417, no. 1, pp. 72–77, 2007.
[91] E. Benedetti, R. Galzio, B. Cinque, et al., “Biomolecular
characterization of human glioblastoma cells in primary
cultures: diﬀerentiating and antiangiogenic eﬀects of natural
and synthetic PPARγ agonists,” Journal of Cellular Physiology,
vol. 217, no. 1, pp. 93–102, 2008.
[92] N. Strakova, J. Ehrmann, J. Bartos, J. Malikova, J. Dolezel,
and Z. Kolar, “Peroxisome proliferator-activated receptors
(PPAR) agonists aﬀect cell viability, apoptosis and expression
ofcellcyclerelatedproteinsincelllinesofglialbraintumors,”
Neoplasma, vol. 52, no. 2, pp. 126–136, 2005.
[93] R. Coras, A. H¨ olsken, S. Seufert, et al., “The peroxisome
proliferator-activatedreceptor-γ agonisttroglitazoneinhibits
transforming growth factor-β -mediated glioma cell migra-
tion and brain invasion,” Molecular Cancer Therapeutics, vol.
6, no. 6, pp. 1745–1754, 2007.
[94] N. Yamada, M. Kato, H. Yamashita, et al., “Enhanced
expression of transforming growth factor-β and its type-I
and type-II receptors in human glioblastoma,” International
Journal of Cancer, vol. 62, no. 4, pp. 386–392, 1995.
[95] T. Kawataki, H. Naganuma, A. Sasaki, H. Yoshikawa, K.
Tasaka, and H. Nukui, “Correlation of thrombospondin-1





vivo,” Nature Medicine, vol. 5, no. 2, pp. 157–163, 1999.
[97] A. Ashkenazi, R. C. Pai, S. Fong, et al., “Safety and antitumor
activity of recombinant soluble Apo2 ligand,” Journal of
Clinical Investigation, vol. 104, no. 2, pp. 155–162, 1999.
[98] K. Schultze, B. B¨ ock, A. Eckert, et al., “Troglitazone sensitizes
tumorcellstoTRAIL-inducedapoptosisviadown-regulationPPAR Research 9
of FLIP and Survivin,” Apoptosis, vol. 11, no. 9, pp. 1503–
1512, 2006.
[99] E. Benedetti, R. Galzio, G. Laurenti, et al., “Lipid metabolism
impairment in human gliomas: expression of peroxiso-
mal proteins in human gliomas at diﬀerent grades of
malignancy,” International Journal of Immunopathology and
Pharmacology. In press.
[100] T. Servidei, R. Morosetti, C. Ferlini, et al., “The cellular
response to PPARγ ligands is related to the phenotype of
neuroblastoma cell lines,” Oncology Research, vol. 14, no. 7-
8, pp. 345–354, 2004.
[101] A. O. Isaac, I. Kawikova, A. L. M. Bothwell, C. K. Daniels,
and J. C. K. Lai, “Manganese treatment modulates the
expression of peroxisome proliferator-activated receptors
in astrocytoma and neuroblastoma cells,” Neurochemical
Research, vol. 31, no. 11, pp. 1305–1316, 2006.
[102] S. Falone, M. R. Grossi, B. Cinque, et al., “Fifty hertz
extremely low-frequency electromagnetic ﬁeld causes
changes in redox and diﬀerentiative status in neuroblastoma
cells,” International Journal of Biochemistry and Cell Biology,
vol. 39, no. 11, pp. 2093–2106, 2007.
[103] H. A. Rodway, A. N. Hunt, J. A. Kohler, A. D. Postle, and K.
A. Lillycrop, “Lysophosphatidic acid attenuates the cytotoxic
and degree of peroxisome proliferator-activated receptor
γ activation induced by 15-deoxyΔ12,14-prostaglandin J2 in
neuroblastoma cells,” Biochemical Journal, vol. 382, no. 1, pp.
83–91, 2004.
[104] S. W. Han, M. E. Greene, J. Pitts, R. K. Wada, and N. Sidell,
“Novel expression and function of peroxisome proliferator-
activatedreceptorγ (PPARγ)inhumanneuroblastomacells,”
Clinical Cancer Research, vol. 7, no. 1, pp. 98–104, 2001.
[105] S. Giri, R. Rattan, A. K. Singh, and I. Singh, “The 15-deoxy-
δ12,14-prostaglandin J2 inhibits the inﬂammatory response
in primary rat astrocytes via down-regulating multiple steps
in phosphatidylinositol 3-kinase-akt-NF-κB-p300 pathway
independent of peroxisome proliferator-activated receptor
γ,” Journal of Immunology, vol. 173, no. 8, pp. 5196–5208,
2004.
[106] V.C.Emmans,H.A.Rodway,A.N.Hunt,andK.A.Lillycrop,
“Regulation of cellular processes by PPARγ ligands in neu-
roblastoma cells is modulated by the level of retinoblastoma
protein expression,” Biochemical Society Transactions, vol. 32,
no. 5, pp. 840–842, 2004.
[107] A. Rossi, P. Kapahi, G. Natoli, et al., “Anti-inﬂammatory
cyclopentenone prostaglandins are direct inhibitors of IκB
kinase,” Nature, vol. 403, no. 6765, pp. 103–108, 2000.
[108] U. Valentiner, M. Carlsson, R. Erttmann, H. Hilde-
brandt, and U. Schumacher, “Ligands for the peroxisome
proliferator-activated receptor-γ have inhibitory eﬀects on
growth of human neuroblastoma cells in vitro,” Toxicology,
vol. 213, no. 1-2, pp. 157–168, 2005.
[109] I.Cellai,S.Benvenuti,P.Luciani,etal.,“Antineoplasticeﬀects
ofrosiglitazoneandPPARγ transactivationinneuroblastoma
cells,” British Journal of Cancer, vol. 95, no. 7, pp. 879–888,
2006.
[110] S. Di Loreto, B. D’Angelo, M. A. D’Amico, et al., “PPARβ
agonists trigger neuronal diﬀerentiation in the human neu-
roblastoma cell line SH-SY5Y,” Journal of Cellular Physiology,
vol. 211, no. 3, pp. 837–847, 2007.